Clinical data | |
---|---|
Trade names | Wainua |
Other names | AKCEA-TTR-LRx |
AHFS/Drugs.com | Eplontersen |
License data |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
Eplontersen, sold under the brand name Wainua, is a medication used for the treatment of transthyretin-mediated amyloidosis.[1] It is a transthyretin-directed antisense oligonucleotide.[1] It was developed to treat hereditary transthyretin amyloidosis by Ionis Pharmaceuticals and AstraZeneca.[2][3][4][5]
It was approved for medical use in the United States in December 2023.[6][7][8]
Eplontersen is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.[1]
Eplontersen is the international nonproprietary name.[9]